Results 111 to 120 of about 493,830 (358)

SPARCL1 and NT‐proBNP as biomarkers of right ventricular‐to‐pulmonary artery uncoupling in pulmonary hypertension

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr   +15 more
wiley   +1 more source

Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials

open access: yesESC Heart Failure, EarlyView.
This systematic review identified 24 clinical trials of medical device and surgical interventions for HFpEF, with 16 demonstrating at least safety and feasibility, but little evidence of long‐term benefit. Phenotype‐based responses suggest that certain interventions may benefit specific HFpEF subgroups, yet most trials suffered from heterogeneous ...
Kurdo Araz   +5 more
wiley   +1 more source

Risk factors and progression of the left ventricular myocardial hypertrophy [PDF]

open access: yesСаратовский научно-медицинский журнал, 2015
Tftea/mofthis workisto study the left ventricular myocardial hypertrophy. Materials and methods: In the study that was held in period from 2008 to 2013 years and covers group of 7959 workers of locomotive brigades of Transbaika-lian railway.
Lazutkina A.Yu., Gorbunov V.V.
doaj  

The emerging role of Nrf2 in heart failure: From cardioprotection to therapeutic approaches

open access: yesESC Heart Failure, EarlyView.
Nrf2 signalling is impaired in heart failure, contributing to oxidative stress, mitochondrial dysfunction, and ferroptosis, which drive neurohormonal activation, inflammation, and ischaemia‐reperfusion injury. This loss of Nrf2 activity exacerbates hypertension, diabetic cardiomyopathy, and cardiotoxicity, accelerating progression to overt heart ...
Emiliano Fiori   +9 more
wiley   +1 more source

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

open access: yesESC Heart Failure, EarlyView.
Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra   +25 more
wiley   +1 more source

Pathogenic glycosyltransferase genes and potential therapeutic drugs in pressure overload‐induced heart failure

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Protein glycosylation regulated by glycosyltransferases is an important type of post‐translational modification. The role of the glycosyltransferase genes (GTGs) in heart failure (HF) remains unclear and requires further investigation.
Jiahe Wu   +5 more
wiley   +1 more source

Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD.

open access: yesJournal of the American Society of Nephrology, 2017
Markus P. Schneider   +17 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy